RKTO Rocket One Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1711786 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY2.2%
TTM EPS YoY40.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-152.0%
ROA-132.9%
ROIC (approx.)-1,024.5%
Asset turnover—
Leverage & solvency
Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.55x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-10.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $5.95M | $3.25M | $3.74M | $4.93M | $7.35M |
| SG&A expense | $6.41M | $4.97M | $4.21M | $6.13M | — |
| Operating income | -$12.36M | -$8.22M | -$7.95M | -$11.07M | -$14.10M |
| Pretax income | -$12.40M | -$8.11M | — | — | — |
| Net income | -$12.47M | -$8.19M | -$8.11M | -$11.37M | -$14.31M |
| EPS (basic) | -0.90 | -1.28 | -2.38 | -9.50 | -16.02 |
| EPS (diluted) | -0.90 | -1.28 | -2.38 | -9.50 | -16.02 |
| Weighted avg. shares (diluted) | 13.81M | 6.38M | 3.41M | 1.20M | 893,226 |
| Balance sheet | |||||
| Cash & equivalents | $6.25M | $7.04M | $9.29M | $6.43M | $8.54M |
| Short-term investments | — | — | — | $209,320 | — |
| Current assets | $6.86M | $7.64M | $10.15M | $7.71M | $10.58M |
| Total assets | $7.60M | $7.71M | $10.24M | $7.74M | $10.99M |
| Current liabilities | $1.45M | $831,197 | $678,657 | $1.39M | $867,787 |
| Total liabilities | $1.45M | $833,906 | $704,983 | $1.64M | $1.10M |
| Shareholders' equity | $6.15M | $6.88M | $9.54M | $6.11M | $9.88M |
| Shares outstanding | 15.51M | 8.04M | 4.35M | 1.30M | 959,009 |
| Cash flow statement | |||||
| Operating cash flow | -$9.80M | -$6.98M | -$8.45M | -$9.30M | -$12.09M |
| Investing cash flow | -$300,000 | — | — | $1.16M | -$165,355 |
| Financing cash flow | $9.31M | $4.74M | $11.32M | $6.04M | $18.19M |
| Stock-based compensation | $1.19M | $804,277 | $216,428 | $620,798 | $1.32M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.